Brief: Promis Neurosciences Reports Top-Line Data From Phase 1A Alzheimer's Trial

ProMIS Neurosciences

26/07/2024 13:38

July 26 (Reuters) - ProMIS Neurosciences Inc  PMN.O :
    * PROMIS NEUROSCIENCES REPORTS POSITIVE TOP-LINE DATA FROM
ITS
PHASE 1A ALZHEIMER'S TRIAL
    * PROMIS NEUROSCIENCES: RESULTS DEMONSTRATED FAVORABLE
SAFETY
PROFILE AND TOLERABILITY ACROSS FOUR ASCENDING DOSE LEVELS IN
HEALTHY VOLUNTEERS
    * PROMIS NEUROSCIENCES: TOPLINE RESULTS SHOWED DOSE
DEPENDENT
LEVELS OF PMN310 ANTIBODY IN CEREBROSPINAL FLUID
    * PROMIS NEUROSCIENCES INC: RESULTS WILL INFORM DOSING OF
PHASE 1B
CLINICAL TRIAL IN ALZHEIMER'S PATIENTS, WHICH IS ON TRACK TO
INITIATE IN H2

Source text for Eikon:  ID:nGNX8DwHBH 
Further company coverage:  PMN.O 

 ((Reuters.Briefs@thomsonreuters.com;))